开云app官网登录入口网页版-官方正版

#GLP-1#

111篇内容 | 3178人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2225378, encodeId=b3db22253e8f1, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a> <a href='/topic/show?id=192611892053' target=_blank style='color:#2F92EE;'>#EASD 2024#</a>, objectTitle=降糖减重更胜一筹，研究揭示GLP-1类双重激动剂的胰岛素影响 | EASD 2024, objectType=article, longId=842990, objectId=7397842990f0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240906/1725617725555_8538692.jpg, objectUrl=/article/show_article.do?id=7397842990f0, replyNumber=0, likeNumber=11, createdTime=2024-09-12, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7397842990f0, moduleTitle=降糖减重更胜一筹，研究揭示GLP-1类双重激动剂的胰岛素影响 | EASD 2024, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7397842990f0)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2224827, encodeId=f057222482e0c, content=<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=2ad5104395dc' target=_blank style='color:#2F92EE;'>#糖尿病#</a></a> <a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a> <a href='/topic/show?id=f4b1e4464ae' target=_blank style='color:#2F92EE;'>#神经系统疾病#</a>, objectTitle=一药多效！降糖减重，还预防中风、痴呆？GLP-1药物促进大脑健康的潜力多大？|盘点, objectType=article, longId=842271, objectId=e20e8422e1db, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240703/1719981273634_5579292.jpg, objectUrl=/article/show_article.do?id=e20e8422e1db, replyNumber=0, likeNumber=9, createdTime=2024-09-09, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e20e8422e1db, moduleTitle=一药多效！降糖减重，还预防中风、痴呆？GLP-1药物促进大脑健康的潜力多大？|盘点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e20e8422e1db)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2208488, encodeId=4d23220848829, content=<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=2ad5104395dc' target=_blank style='color:#2F92EE;'>#糖尿病#</a></a> <a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=ATVB 浙二医院内分泌科郑超团队发现GLP-1(32-36)非胰岛素依赖的促糖尿病下肢血管新生新作用, objectType=article, longId=828861, objectId=d559828861e7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240605/1717576337456_5579292.png, objectUrl=/article/show_article.do?id=d559828861e7, replyNumber=0, likeNumber=76, createdTime=2024-06-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d559828861e7, moduleTitle=ATVB 浙二医院内分泌科郑超团队发现GLP-1(32-36)非胰岛素依赖的促糖尿病下肢血管新生新作用, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d559828861e7)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2189238, encodeId=10c6218923822, content=<a href='/topic/show?id=5903e416813' target=_blank style='color:#2F92EE;'>#神经元#</a> <a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a> <a href='/topic/show?id=969b84833fc' target=_blank style='color:#2F92EE;'>#脑干#</a>, objectTitle=Nature：新研究发现两条并行的途径控制着进食, objectType=article, longId=813907, objectId=266781390e9a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20240219/1708355435065_2185383.png, objectUrl=/article/show_article.do?id=266781390e9a, replyNumber=0, likeNumber=71, createdTime=2024-02-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2184452, encodeId=70bb21844525b, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a> <a href='/topic/show?id=2a622434820' target=_blank style='color:#2F92EE;'>#交感神经#</a> <a href='/topic/show?id=6d47104e3090' target=_blank style='color:#2F92EE;'>#血糖调控#</a> <a href='/topic/show?id=6b1311063690' target=_blank style='color:#2F92EE;'>#肠道L细胞#</a>, objectTitle=Neuron：曾文文/周鸿团队发现肠道交感神经-L细胞单元通过调控GLP-1分泌影响机体血糖调控和大脑认知功能, objectType=article, longId=811291, objectId=acfe81129159, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20240123/ea69d43511d64293a8d90a88b8b8acf7.jpg, objectUrl=/article/show_article.do?id=acfe81129159, replyNumber=0, likeNumber=129, createdTime=2024-01-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=加利福尼亚, moduleDTOList=[ModuleDTO(moduleId=acfe81129159, moduleTitle=Neuron：曾文文/周鸿团队发现肠道交感神经-L细胞单元通过调控GLP-1分泌影响机体血糖调控和大脑认知功能, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=acfe81129159)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2182374, encodeId=2dc821823e427, content=<a href='/topic/show?id=53c66e0011b' target=_blank style='color:#2F92EE;'>#炎症#</a> <a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a> <a href='/topic/show?id=a4331046697a' target=_blank style='color:#2F92EE;'>#2 型糖尿病#</a>, objectTitle=Cell Metab：揭示 GLP-1 激动剂在大脑中发挥作用新机制, objectType=article, longId=809301, objectId=15ea8093018f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20240113/1705146682786_2185383.png, objectUrl=/article/show_article.do?id=15ea8093018f, replyNumber=0, likeNumber=64, createdTime=2024-01-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2177398, encodeId=e07f21e7398df, content=<a href='/topic/show?id=3ad9818917c' target=_blank style='color:#2F92EE;'>#肥胖#</a> <a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=减重近27%！GLP-1类减肥“神药”，今年这5款最亮眼 | 《自然》子刊年度盘点, objectType=article, longId=806869, objectId=1de680686972, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016274166_4754896.png, objectUrl=/article/show_article.do?id=1de680686972, replyNumber=0, likeNumber=81, createdTime=2023-12-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1de680686972, moduleTitle=减重近27%！GLP-1类减肥“神药”，今年这5款最亮眼 | 《自然》子刊年度盘点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1de680686972)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2118789, encodeId=3d6f2118e8947, content=<a href='/topic/show?id=f3ad840081f' target=_blank style='color:#2F92EE;'>#胰高血糖素样肽-1#</a> （<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>）为基础的药物，包括<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>（GLP-1RA）和<a href='/topic/show?id=788a24043af' target=_blank style='color:#2F92EE;'>#二肽基肽酶-4抑制剂#</a> （<a href='/topic/show?id=03d2622088' target=_blank style='color:#2F92EE;'>#DPP4i#</a>），是用于治疗<a href='/topic/show?id=d20f1090c2' target=_blank style='color:#2F92EE;'>#2型糖尿病#</a>的<a href='/topic/show?id=98e610556057' target=_blank style='color:#2F92EE;'>#肠促胰素类药物#</a>。除了肠促胰素效应外，GLP-1为基础的药物还具有<a href='/topic/show?id=98c0553894c' target=_blank style='color:#2F92EE;'>#抗炎#</a>作用。然而，既往一项研究报告使用DPP4i会增加<a href='/topic/show?id=2e6e6e0315d' target=_blank style='color:#2F92EE;'>#炎症性肠病#</a>（IBD）风险。, objectTitle=ECCO 2023 | GLP-1为基础的药物与炎症性肠病风险：来自国家队列研究的真实世界证据, objectType=article, longId=762356, objectId=7d8be62356b3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20230111/361cfc26c42642a891ede2db100a3ffa.jpg, objectUrl=/article/show_article.do?id=7d8be62356b3, replyNumber=0, likeNumber=162, createdTime=2023-03-11, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7d8be62356b3, moduleTitle=ECCO 2023 | GLP-1为基础的药物与炎症性肠病风险：来自国家队列研究的真实世界证据, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7d8be62356b3)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2113720, encodeId=72362113e2059, content=2023年<a href='/topic/show?id=51d964412c0' target=_blank style='color:#2F92EE;'>#沃尔夫奖#</a>揭晓，<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>研究和<a href='/topic/show?id=45bd1556333' target=_blank style='color:#2F92EE;'>#RNA甲基化#</a>研究分别获奖，<a href='/topic/show?id=17181052e341' target=_blank style='color:#2F92EE;'>#何川#</a>超级大牛！<a href='/topic/show?id=ac501119586' target=_blank style='color:#2F92EE;'>#m6A#</a><a href='/topic/show?id=5b109025320' target=_blank style='color:#2F92EE;'>#表观遗传学#</a>, objectTitle=2023年沃尔夫奖揭晓，GLP-1研究和RNA甲基化研究分别获奖, objectType=article, longId=759016, objectId=fe19e59016fb, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20230111/ab1da446af4f4fbd8ce5de0c22635bb0.jpg, objectUrl=/article/show_article.do?id=fe19e59016fb, replyNumber=0, likeNumber=107, createdTime=2023-02-09, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=fe19e59016fb, moduleTitle=2023年沃尔夫奖揭晓，GLP-1研究和RNA甲基化研究分别获奖, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fe19e59016fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422780, encodeId=07211422e80a0, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Cardiovasc Diabetol：GLP-1受体激动剂与SGLT-2抑制剂在2型糖尿病的有效性和安全性, objectType=article, longId=739436, objectId=f1a5e39436f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1a5e39436f8, replyNumber=0, likeNumber=80, createdTime=2022-09-17, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1a5e39436f8, moduleTitle=Cardiovasc Diabetol：GLP-1受体激动剂与SGLT-2抑制剂在2型糖尿病的有效性和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f1a5e39436f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422778, encodeId=4e201422e7893, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Diabetes ：GIP和GLP-1增强磺脲类药物诱导肝细胞核因子1a突变携带者的胰岛素分泌, objectType=article, longId=738901, objectId=d917e38901bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d917e38901bd, replyNumber=0, likeNumber=79, createdTime=2022-09-12, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d917e38901bd, moduleTitle=Diabetes ：GIP和GLP-1增强磺脲类药物诱导肝细胞核因子1a突变携带者的胰岛素分泌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d917e38901bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422777, encodeId=d2a21422e7760, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Front Pharmacol：2型糖尿病患者使用DPP-4i、GLP-1 RAs和SGLT-2i的骨折风险, objectType=article, longId=736722, objectId=3a36e36722e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a36e36722e3, replyNumber=0, likeNumber=64, createdTime=2022-08-25, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a36e36722e3, moduleTitle=Front Pharmacol：2型糖尿病患者使用DPP-4i、GLP-1 RAs和SGLT-2i的骨折风险, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3a36e36722e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422776, encodeId=64b51422e763a, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=持续超24小时！研究开发出兼具稳定性和降糖作用的GLP-1类似物, objectType=article, longId=734413, objectId=d541e3441308, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d541e3441308, replyNumber=0, likeNumber=78, createdTime=2022-08-06, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d541e3441308, moduleTitle=持续超24小时！研究开发出兼具稳定性和降糖作用的GLP-1类似物, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d541e3441308)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422775, encodeId=d3031422e758f, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=JAMA Intern Med：GLP-1RA与胆囊或胆道事件相关, objectType=article, longId=729050, objectId=44efe290500e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44efe290500e, replyNumber=0, likeNumber=69, createdTime=2022-06-11, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44efe290500e, moduleTitle=JAMA Intern Med：GLP-1RA与胆囊或胆道事件相关, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=44efe290500e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422774, encodeId=b0c01422e7471, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响, objectType=article, longId=723796, objectId=c62be2379617, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c62be2379617, replyNumber=0, likeNumber=65, createdTime=2022-04-09, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c62be2379617, moduleTitle=Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c62be2379617)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422773, encodeId=659b1422e730e, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Cardiovasc Diabetol：GLP-1激动剂 vs SGLT-2抑制剂 vs DPP-4抑制剂对T2DM患者心肾结局的影响, objectType=article, longId=301367, objectId=c4b830136e91, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4b830136e91, replyNumber=0, likeNumber=63, createdTime=2022-03-23, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4b830136e91, moduleTitle=Cardiovasc Diabetol：GLP-1激动剂 vs SGLT-2抑制剂 vs DPP-4抑制剂对T2DM患者心肾结局的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c4b830136e91)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422772, encodeId=f7cb1422e7259, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=JAMA子刊：GLP-1受体激动剂与DPP-4抑制剂的使用与2型糖尿病和晚期慢性肾病患者死亡率的关系, objectType=article, longId=300317, objectId=525d30031e63, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=525d30031e63, replyNumber=0, likeNumber=95, createdTime=2022-03-10, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=525d30031e63, moduleTitle=JAMA子刊：GLP-1受体激动剂与DPP-4抑制剂的使用与2型糖尿病和晚期慢性肾病患者死亡率的关系, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=525d30031e63)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422771, encodeId=f2ab1422e7110, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=BM子刊：GLP-1受体激动剂治疗T2DM患者的真实体重变化、依从性和停药情况, objectType=article, longId=295500, objectId=4e5b295500be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e5b295500be, replyNumber=0, likeNumber=90, createdTime=2022-02-13, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e5b295500be, moduleTitle=BM子刊：GLP-1受体激动剂治疗T2DM患者的真实体重变化、依从性和停药情况, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4e5b295500be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422770, encodeId=8b941422e708a, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=JAHA：SGLT2i和GLP-1RA对老年患者的心血管疗效比较, objectType=article, longId=295380, objectId=927829538021, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=927829538021, replyNumber=0, likeNumber=86, createdTime=2022-02-11, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=927829538021, moduleTitle=JAHA：SGLT2i和GLP-1RA对老年患者的心血管疗效比较, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=927829538021)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422769, encodeId=14211422e69ea, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=JAMA：GLP-1受体激动剂体重控制谁更强？索马鲁肽减重效果优于利拉鲁肽, objectType=article, longId=293924, objectId=e7922939240b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7922939240b, replyNumber=0, likeNumber=93, createdTime=2022-01-14, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7922939240b, moduleTitle=JAMA：GLP-1受体激动剂体重控制谁更强？索马鲁肽减重效果优于利拉鲁肽, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e7922939240b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

GLP-1

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#GLP-1# #EASD 2024#

降糖减重更胜一筹，研究揭示GLP-1类双重激动剂的胰岛素影响 | EASD 2024

2024-09-12发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#糖尿病# #GLP-1# #神经系统疾病#

一药多效！降糖减重，还预防中风、痴呆？GLP-1药物促进大脑健康的潜力多大？|盘点

2024-09-09发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#糖尿病# #GLP-1#

ATVB 浙二医院内分泌科郑超团队发现GLP-1(32-36)非胰岛素依赖的促糖尿病下肢血管新生新作用

2024-06-05发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#神经元# #GLP-1# #脑干#

2024-02-25发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#GLP-1# #交感神经# #血糖调控# #肠道L细胞#

Neuron：曾文文/周鸿团队发现肠道交感神经-L细胞单元通过调控GLP-1分泌影响机体血糖调控和大脑认知功能

2024-01-28发表于加利福尼亚

梅斯管理员 (审核中...)

前往app查看评论内容

#炎症# #GLP-1# #2 型糖尿病#

2024-01-18发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#肥胖# #GLP-1#

减重近27%！GLP-1类减肥“神药”，今年这5款最亮眼 | 《自然》子刊年度盘点

2023-12-26发表于上海

showtest (审核中...)

前往app查看评论内容

全文收起 #胰高血糖素样肽-1# （#GLP-1#）为基础的药物，包括#GLP-1受体激动剂#（GLP-1RA）和#二肽基肽酶-4抑制剂# （#DPP4i#），是用于治疗#2型糖尿病#的#肠促胰素类药物#。除了肠促胰素效应外，GLP-1为基础的药物还具有#抗炎#作用。然而，既往一项研究报告使用DPP4i会增加#炎症性肠病#（IBD）风险。

ECCO 2023 | GLP-1为基础的药物与炎症性肠病风险：来自国家队列研究的真实世界证据

2023-03-11发表于上海

showtest (审核中...)

前往app查看评论内容

2023年#沃尔夫奖#揭晓，#GLP-1#研究和#RNA甲基化#研究分别获奖，#何川#超级大牛！#m6A##表观遗传学#

2023年沃尔夫奖揭晓，GLP-1研究和RNA甲基化研究分别获奖

2023-02-09发表于上海

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Cardiovasc Diabetol：GLP-1受体激动剂与SGLT-2抑制剂在2型糖尿病的有效性和安全性

2022-09-17

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Diabetes ：GIP和GLP-1增强磺脲类药物诱导肝细胞核因子1a突变携带者的胰岛素分泌

2022-09-12

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Front Pharmacol：2型糖尿病患者使用DPP-4i、GLP-1 RAs和SGLT-2i的骨折风险

2022-08-25

yibei (审核中...)

前往app查看评论内容

#GLP-1#

持续超24小时！研究开发出兼具稳定性和降糖作用的GLP-1类似物

2022-08-06

yibei (审核中...)

前往app查看评论内容

#GLP-1#

JAMA Intern Med：GLP-1RA与胆囊或胆道事件相关

2022-06-11

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响

2022-04-09

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Cardiovasc Diabetol：GLP-1激动剂 vs SGLT-2抑制剂 vs DPP-4抑制剂对T2DM患者心肾结局的影响

2022-03-23

yibei (审核中...)

前往app查看评论内容

#GLP-1#

JAMA子刊：GLP-1受体激动剂与DPP-4抑制剂的使用与2型糖尿病和晚期慢性肾病患者死亡率的关系

2022-03-10

yibei (审核中...)

前往app查看评论内容

#GLP-1#

BM子刊：GLP-1受体激动剂治疗T2DM患者的真实体重变化、依从性和停药情况

2022-02-13

yibei (审核中...)

前往app查看评论内容

#GLP-1#

JAHA：SGLT2i和GLP-1RA对老年患者的心血管疗效比较

2022-02-11

yibei (审核中...)

前往app查看评论内容

#GLP-1#

JAMA：GLP-1受体激动剂体重控制谁更强？索马鲁肽减重效果优于利拉鲁肽

2022-01-14

科室
- - 订阅+
  - 更多科室
工具
服务